Glide Pharma has appointed a chief financial officer and a director of business development as it prepares to scale up its commercial efforts.
Richard Bungay joins as chief financial officer from Verona, where he had served since September last year. Prior to this he was CEO of fellow UK biotech Chroma Therapeutics having previously been the company’s chief financial officer.
His other previous include director of corporate communications and strategic planning at Celltech and finance director within the respiratory and inflammation therapy area at AstraZeneca.
New director of business development Tony Mills joins Glide from Q Chip where he was chief commercial officer.
Dr Mark Carnegie-Brown, Glide’s CEO, commented: “Both are seasoned industry professionals, and attracting executives of their calibre is a testament to the progress Glide has made since completing a strategic fundraising last year for the scale-up of our device and formulation capabilities.”